Why the study?
Does silencing miR-208a with an antagomir prevent doxorubicin-induced myocyte apoptosis and cardiac dysfunction in eight-week-old female Balb/C mice?
Population
Eight-week-old female Balb/C mice
Comparison
miR-208a antagomir administered 4 days before… vs Control group receiving doxorubicin alone, and…
Design
Preclinical, randomly assigned
Follow-up
7 days
Authors
Loading...
May attenuate doxorubicin cardiotoxicity in mice; leaves open clinical translation of antagomir therapy.
Does silencing miR-208a with an antagomir prevent doxorubicin-induced myocyte apoptosis and cardiac dysfunction in eight-week-old female Balb/C mice?
Silencing miR-208a represents a potential therapeutic strategy to prevent doxorubicin-induced cardiotoxicity by preserving GATA4 and reducing myocyte apoptosis.
Tony et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: